June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Development of in vitro and ex vivo tools for functional characterization of variants of uncertain significance in aniridia
Author Affiliations & Notes
  • Alejandra Tamayo Duran
    Genetics and Genomics, Instituto de Investigacion Sanitaria de la Fundacion Jimenez Diaz, Madrid, Madrid, Spain
    Centro de Investigacion Biomedica en Red de Enfermedades Raras, Madrid, Madrid, Spain
  • María Tarilonte Misas
    Genetics and Genomics, Instituto de Investigacion Sanitaria de la Fundacion Jimenez Diaz, Madrid, Madrid, Spain
  • Jennifer Moya
    Genetics and Genomics, Instituto de Investigacion Sanitaria de la Fundacion Jimenez Diaz, Madrid, Madrid, Spain
  • Patricia Ramos
    Genetics and Genomics, Instituto de Investigacion Sanitaria de la Fundacion Jimenez Diaz, Madrid, Madrid, Spain
  • Saoud Tahsin Swafiri
    Genetics and Genomics, Instituto de Investigacion Sanitaria de la Fundacion Jimenez Diaz, Madrid, Madrid, Spain
    Centro de Investigacion Biomedica en Red de Enfermedades Raras, Madrid, Madrid, Spain
  • Fiona Blanco
    Genetics and Genomics, Instituto de Investigacion Sanitaria de la Fundacion Jimenez Diaz, Madrid, Madrid, Spain
    Centro de Investigacion Biomedica en Red de Enfermedades Raras, Madrid, Madrid, Spain
  • Carmen Ayuso
    Genetics and Genomics, Instituto de Investigacion Sanitaria de la Fundacion Jimenez Diaz, Madrid, Madrid, Spain
    Centro de Investigacion Biomedica en Red de Enfermedades Raras, Madrid, Madrid, Spain
  • Marta Cortón
    Genetics and Genomics, Instituto de Investigacion Sanitaria de la Fundacion Jimenez Diaz, Madrid, Madrid, Spain
    Centro de Investigacion Biomedica en Red de Enfermedades Raras, Madrid, Madrid, Spain
  • Footnotes
    Commercial Relationships   Alejandra Tamayo Duran, None; María Tarilonte Misas, None; Jennifer Moya, None; Patricia Ramos, None; Saoud Tahsin Swafiri, None; Fiona Blanco, None; Carmen Ayuso, None; Marta Cortón, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1565. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alejandra Tamayo Duran, María Tarilonte Misas, Jennifer Moya, Patricia Ramos, Saoud Tahsin Swafiri, Fiona Blanco, Carmen Ayuso, Marta Cortón; Development of in vitro and ex vivo tools for functional characterization of variants of uncertain significance in aniridia. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1565.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : PAX6 mutations lead to aniridia, a panocular disorder that usually involves iris and foveal hypoplasia, cataract, corneal dystrophy, as well as abnormalities of the optic nerve.
Here, we describe the development of two molecular approaches for the functional characterization of coding and non-coding variants with uncertain significance (VUS) and their impact on the canonical PAX6 splicing in aniridia patients.

Methods : For in vitro splice assays, a genomic segment encompassing the region of interest of PAX6 along with flanking sequences was amplified by PCR from genomic DNA and was cloned into an expression vector. VUS were introduced in the wild-type minigene constructs by site-directed mutagenesis. The minigene assays were performed by transient transfection into kidney HEK-293 and/or retinal ARPE-19 cell lines.
For ex vivo splice assays, lymphoblastoid cell lines (LCL) were established by Epstein Barr virus transformation of blood lymphocytes from patients carrying VUS and control healthy individuals.
Both HEK-293 transfected cells and lymphoblastoid cells were harvested and total RNA was extracted and reverse transcribed. The splicing patterns of mRNA transcripts were compared by semiquantitative PCR and sequencing.

Results : We have developed four minigene wild-type constructs involving the full exonic and intronic sequences of PAX6: i) the 5’UTR region (exons 1 to 4), ii) exons 5a and 6, iii) exons 5 to 7 and iv) exons 8 to 11, respectively. To date, a total of 13 variants have been assayed. 11 out 13 showed aberrant splicing patterns that include different mechanisms such as single or multiple exon skipping, exon elongations, intron retentions and new pseudoexon inclusions by the alternative use of cryptic splicing sites.
Ex-vivo expression analysis in LCL from 5 carrier patients showed alterations on splicing patterns. Two out five were also tested by in vitro splice assays and the findings on splicing patterns correlate with those observed in minigene assays.

Conclusions : Minigene PAX6 assays carrying multiple exons and LCL studies are useful strategies to gain insight into the pathogenicity of the poorly explored non-canonical splice PAX6 variants. These methods along with in silico analysis are easy-to-carry approaches for robust splice variant analysis and to help bring molecular diagnosis to aniridia patients.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×